Acorda loses Nasdaq listing to cap biotech’s end
Acorda Therapeutics has been delisted from the Nasdaq Stock Market as a result of non-compliance with Nasdaq’s listing rules. Nasdaq…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
Sanofi advances NK cell engager to Phase II for blood cancer treatment
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use…
-
Candel wins FDA orphan drug designation for pancreatic cancer drug
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for…
-
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
Vertex Pharmaceuticals has agreed to acquire biotech Alpine Immune Sciences for $4.9bn, joining the growing number of pharma spending big on…
-
Lisata wins FDA orphan drug status for bone cancer candidate
The US Food and Drug Administration (FDA) has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) for the treatment…
-
Seaport emerges after $100m raise with ex-Karuna team at helm
Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging with $100m from a financing round. ARCH Venture Partners and…
-
Sensorion raises $16m for gene therapies to treat deafness
Sensorion has secured €14.8m ($16m) from its investors to advance its gene therapy programmes for the treatment of deafness and…
-
England’s MMR vaccinations up 23% following NHS initiative
England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps, and…
-
Obsidian raises $160.5m to advance TIL cell therapy programme
Obsidian Therapeutics has raised $160.5m in a Series C financing round, with plans for the funds to be injected into…
-
Genmab joins ADC arena with $1.8bn ProfoundBio acquisition
Genmab could soon join the growing list of companies targeting the antibody drug conjugate (ADC) market, with the announcement that…